ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
Key Highlights
- ➤ScionxBio and Sanofi signed a worldwide collaboration and licensing agreement
- ➤Sanofi will develop, manufacture, and commercialize extended-exposure mRNA candidates worldwide
- ➤ScionxBio will optimize candidates through in vivo validation using its TERA platform
- ➤Disease areas and financial terms remain undisclosed
Expert Statements
Dr. Adi Gilboa-Geffen, CEO of ScionxBio
“This collaboration with Sanofi is a defining milestone for our company. It validates the revolutionary potential of our AI-driven TERA platform to overcome the historical limitations of mRNA durability. Partnering with a global powerhouse like Sanofi ensures that our innovations in therapeutic RNA reach patients with life-altering protein deficiencies and chronic conditions more rapidly than ever before. I am also deeply grateful to the entire team, whose contributions were instrumental in bringing this collaboration to fruition.”
Dr. Yaniv Erlich, Chairman of the Board and co-founder of ScionxBio
“Collaborating with a world leader like Sanofi is a testament to the scientific rigor and broad applicability of our transformative technology. This partnership accelerates the translation of our platform from the lab to the bedside as we mature our pipeline to serve patients in need across the globe.”
ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics
ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY) to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s proprietary TERA(®) platform.
Get started
Create a free account to read the full story.